The major barrier to effective cancer treatment is the prevention of recurrence and metastasis- no existing therapies prevent recurrence of disease. Ideally, all cancers would be detected and treated early, before the tumor spreads. However, few effective early detection tests are available and many diagnoses are first made at an advanced stage of disease when the prognosis is very poor. While surgery and chemotherapy can slow disease progression, 60 to 90% of cancer patients die from recurrence and metastasis. 

Immunotope has optimized a proprietary immunoproteomics platform that is applicable to immunotherapy development for all solid tumor cancers and is addressing the need for effective detection and curative treatments for cancer by developing

• Early Stage Diagnostic Tests for early treatment of tumors before they have spread, and 

• Active Immunotherapies that enable the patient's own immune system to recognize and destroy tumor cells wherever they arise in the body.

Three conditions are critical for effective active immunotherapy:

• Minimal residual disease setting (e.g., post-surgery and chemotherapy or early stage)

• An effective delivery system to break tolerance and target antigen-presenting cells

• The Right Antigens involved in essential tumor pathways and naturally presented to the immune system 

Immunotope’s immunotherapeutic and diagnostic development platform is based upon the Company's ability to identify: 

• Endogenous, naturally presented antigenic peptides associated with class I and II Major Histocompatibility Complex (MHC) molecules

• Autoantibody-reactive proteins identified by serological analysis 

• Membrane proteins on the surfaces of diseased cells that are putative targets for novel monoclonal antibody therapeutics

Identifying the 'Right Antigens' for Immunotherapy:

Click here to learn more about Immunotope's Antigen Discovery Platform